The KLHL18 Knockout A-549 Polyclonal Cells product comprises a population of A-549 lung adenocarcinoma cells edited via CRISPR/Cas9-mediated targeting of the KLHL18 locus, resulting in a heterogeneous polyclonal knockout cell pool. This polyclonal format provides a robust loss-of-function model for studying KLHL18-dependent processes without clonal selection artifacts, and is suitable for population-level assays where consistent gene disruption is maintained across the culture.
The A-549 host cell line was originally established from the lung adenocarcinoma tissue of a 58-year-old Caucasian male and is widely employed as a model system for non-small cell lung carcinoma (NSCLC) research. These epithelial cells retain characteristics of type II alveolar pneumocytes and exhibit robust growth in adherent culture, making them a convenient and physiologically relevant platform for investigating oncogenic signaling, drug response, and cellular homeostasis mechanisms.
KLHL18 functions as a substrate-specific adaptor for the CUL3-RBX1 E3 ubiquitin ligase complex, directing the polyubiquitination and subsequent proteasomal degradation of key substrates. A central target is the autophagy-initiating kinase ULK1; by promoting ULK1 turnover, KLHL18 negatively regulates autophagy induction. This axis is modulated by upstream mTORC1 signaling and is subject to feedback from ULK1 itself. Additional interacting factors include CUL3, RBX1, and ubiquitin-conjugating E2 enzymes, while pathway components ATG13 and FIP200 further contextualize KLHL18 within the autophagy initiation machinery.
In the A-549 lung adenocarcinoma context, KLHL18-mediated suppression of autophagy is particularly relevant because autophagy can play dual roles in cancer, either suppressing tumor initiation or supporting established tumor survival under stress. Disruption of KLHL18 in these cells is expected to stabilize ULK1, leading to elevated autophagy flux and potentially altering cellular responses to nutrient deprivation, chemotherapeutic agents, and proteotoxic stress. This model thereby enables dissection of autophagy-dependent mechanisms that contribute to lung adenocarcinoma progression and drug resistance.
Researchers can employ these KLHL18 knockout polyclonal cells in a variety of molecular and functional assays. Western blotting for KLHL18, ULK1, and the autophagosome marker LC3 can confirm altered protein expression and autophagic activity. Co-immunoprecipitation can validate disrupted interaction between KLHL18 and CUL3, while ubiquitination assays probe ULK1 modification levels. Autophagy flux measurements using LC3-II turnover in the presence of lysosomal inhibitors, combined with cell proliferation assays (MTT or BrdU), provide quantitative insights into the phenotypic consequences of KLHL18 loss. These applications make the cell population a versatile tool for autophagy research, cancer cell biology, and proteostasis studies. For further information or to request a quotation, please contact Ascent Research.
